In response to emerging insights on semaglutide's safety and efficacy, a new standardization for cerebral blood flow (CBF) assessment is set to simplify patient stratification and improve monitoring protocols. By defining 'normalization' thresholds and instituting longitudinal CBF monitoring, the initiative aims to reduce gastrointestinal discontinuation rates through enhanced patient education and symptom management. As semaglutide continues to gain traction in obesity and diabetes management, this proactive approach addresses earlier concerns, fostering a controlled risk posture for its use across diverse patient populations.
Title not available for this citation.
“Cresyl violet staining demonstrated IKVAV-PA treatment significantly reduced infarct size when compared to saline treated animals.”
Title not available for this citation.
“Systemically administered IKVAV-PA crossed the blood-brain barrier and was primarily detected within the ischemic hemisphere.”
Title not available for this citation.
“CBF in patients with cortical hyperperfusion (CHP) before treatment and decreased CBF after treatment (27 patients) or with no CHP before treatment and increased CBF after treatment (18 patients) became more normal.”
Title not available for this citation.
“Notably, the latter group showed the highest percentage of patients with a > 50% decrease in monthly headache days (94%).”
Title not available for this citation.
“Approximately 90% of patients with no CHP before treatment and decreased CBF after treatment (19 patients) showed inappropriate changes in CBF after treatment, with CBF decreasing below normal levels.”
Title not available for this citation.
“Oral delivery of protein and peptide therapeutics (PPs) offers a non-invasive, patient-friendly alternative to parenteral administration.”
Title not available for this citation.
“yet faces multiple formidable barriers due to the complex gastrointestinal (GI) environment.”
Title not available for this citation.
“This review provides an overview of the latest advances of strategies developed to overcome the four main GI barriers: the harsh pH environment, enzymatic degradation, the mucus layer, and the intestinal epithelial barrier.”
Title not available for this citation.
“We critically evaluate various approaches including chemical modifications, permeation enhancers, encapsulation techniques, and novel delivery systems like microneedles and nanoparticle-based carriers.”
Title not available for this citation.
“Furthermore, we examine the current challenges associated with oral PPs drug delivery systems and explore future directions aimed at achieving successful therapeutic outcomes.”
Title not available for this citation.
“Semaglutide and tirzepatide: Oral cavity effects of weight-loss therapies.”
Title not available for this citation.
“Our meta-analysis suggests GLP-1 RAs improve BMI and show a modest decrease in ALT levels in youths with obesity.”